Xenon to Present at Stifel 2025 Virtual CNS Forum
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the upcoming Stifel 2025 Virtual CNS Forum, scheduled for March 18-19, 2025. The company will deliver a fireside chat presentation, which will be accessible via live audio webcast on the 'Investors' section of Xenon's website.
Xenon specializes in developing ion channel product portfolio targeting areas with high unmet medical needs, particularly epilepsy and depression. Their leading product, Azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications. This compound represents the most advanced, clinically validated potassium channel modulator in development.
Xenon Pharmaceuticals (Nasdaq: XENE), un'azienda biofarmaceutica focalizzata sulle neuroscienze, ha annunciato la sua partecipazione al prossimo Stifel 2025 Virtual CNS Forum, previsto per il 18-19 marzo 2025. L'azienda presenterà una chat informale, che sarà accessibile tramite webcast audio dal vivo nella sezione 'Investitori' del sito web di Xenon.
Xenon si specializza nello sviluppo di un portafoglio di prodotti per canali ionici che mira a soddisfare aree con elevate esigenze mediche non soddisfatte, in particolare l'epilessia e la depressione. Il loro prodotto di punta, Azetukalner, è un nuovo apritore del canale di potassio Kv7 attualmente in fase di sviluppo clinico avanzato per molteplici indicazioni. Questo composto rappresenta il modulatore del canale di potassio clinicamente validato più avanzato in fase di sviluppo.
Xenon Pharmaceuticals (Nasdaq: XENE), una compañía biofarmacéutica enfocada en neurociencias, ha anunciado su participación en el próximo Stifel 2025 Virtual CNS Forum, programado para el 18-19 de marzo de 2025. La compañía ofrecerá una presentación en formato de charla informal, que será accesible a través de una transmisión en vivo de audio en la sección 'Inversores' del sitio web de Xenon.
Xenon se especializa en el desarrollo de un portafolio de productos de canales iónicos que se enfoca en áreas con altas necesidades médicas no satisfechas, particularmente la epilepsia y la depresión. Su producto principal, Azetukalner, es un nuevo abridor del canal de potasio Kv7 que actualmente se encuentra en desarrollo clínico avanzado para múltiples indicaciones. Este compuesto representa el modulador de canal de potasio clínicamente validado más avanzado en desarrollo.
Xenon Pharmaceuticals (Nasdaq: XENE), 신경과학에 중점을 둔 생명공학 회사,가 다가오는 Stifel 2025 Virtual CNS Forum에 참여할 것이라고 발표했습니다. 이 포럼은 2025년 3월 18-19일에 예정되어 있습니다. 회사는 '투자자' 섹션의 Xenon 웹사이트에서 실시간 오디오 웹캐스트를 통해 접근할 수 있는 대화 형식의 발표를 진행할 예정입니다.
Xenon은 이온 채널 제품 포트폴리오를 개발하는 데 전문화되어 있으며, 특히 간질과 우울증과 같은 높은 의료 수요가 있는 분야를 목표로 하고 있습니다. 그들의 주요 제품인 Azetukalner는 현재 여러 적응증에 대해 후기 단계의 임상 개발 중인 새로운 Kv7 칼륨 채널 개방제입니다. 이 화합물은 개발 중인 가장 진보된 임상적으로 검증된 칼륨 채널 조절제를 나타냅니다.
Xenon Pharmaceuticals (Nasdaq: XENE), une entreprise biopharmaceutique axée sur les neurosciences, a annoncé sa participation au prochain Stifel 2025 Virtual CNS Forum, prévu pour les 18 et 19 mars 2025. L'entreprise présentera une discussion informelle, qui sera accessible via un webcast audio en direct dans la section 'Investisseurs' du site web de Xenon.
Xenon se spécialise dans le développement d'un portefeuille de produits de canaux ioniques ciblant des domaines avec de grands besoins médicaux non satisfaits, notamment l'épilepsie et la dépression. Leur produit phare, Azetukalner, est un nouvel ouvreur de canal de potassium Kv7 actuellement en développement clinique avancé pour plusieurs indications. Ce composé représente le modulateur de canal de potassium le plus avancé et cliniquement validé en développement.
Xenon Pharmaceuticals (Nasdaq: XENE), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften, hat seine Teilnahme am bevorstehenden Stifel 2025 Virtual CNS Forum angekündigt, das für den 18.-19. März 2025 geplant ist. Das Unternehmen wird eine informelle Präsentation halten, die über einen Live-Audio-Webcast im Bereich 'Investoren' auf der Website von Xenon zugänglich sein wird.
Xenon ist auf die Entwicklung eines Produktportfolios für Ionenkanäle spezialisiert, das sich auf Bereiche mit hohen unerfüllten medizinischen Bedürfnissen konzentriert, insbesondere Epilepsie und Depression. Ihr Hauptprodukt, Azetukalner, ist ein neuartiger Kv7-Kaliumkanalöffner, der sich derzeit in der späten klinischen Entwicklungsphase für mehrere Indikationen befindet. Diese Verbindung stellt den fortschrittlichsten, klinisch validierten Kaliumkanalmodulator in der Entwicklung dar.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025.
Fireside Chat Presentation Details:
| Date: | Wednesday, March 19, 2025 |
| Time: | 12:00-12:25 PM Eastern Time |
| Webcast: | Register here |
| Presenter: | Dr. Chris Kenney, Chief Medical Officer |
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When is Xenon Pharmaceuticals (XENE) presenting at the Stifel 2025 Virtual CNS Forum?
What is Xenon's (XENE) lead drug candidate and what does it target?
Which therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?
How can investors access Xenon's (XENE) presentation at the Stifel CNS Forum?
